Dr Thomas Hecht
Thomas is Chairman of the Board since 2012. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Today, he provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies.
He also serves as Chairman of Affimed NV, Vaximm AG and Aelix Therapeutics SA. In 2009, with the acquisition by Alcon, he stepped down as Chairman of ESBATech AG; and in 2015, with the acquisition by Baxter International Inc., from his post as Chairman of the Supervisory Council of SuppreMol GmbH.
Thomas earned his MD at the University of Freiburg.
Maina is Director of Healthcare Investments for Imperial Innovations and has extensive start-up experience gained through working at biotechnology ventures for over 10 years, both in the United States and the UK.
She has served as a board member for Molecular Vision and was previously a Senior Scientist at Celltech (formerly Oxford Glyco Sciences), where she was responsible for the successful management of several drug discovery projects.
Her experience in the United States includes Chimeric Therapies, a cell therapy start-up based in Philadelphia.
Maina has an MBA from the Tanaka Business School, Imperial College London and a BSc in biochemistry from the University of Texas.
Dr Nigel Burns
Nigel has extensive experience in product and company management and has held a series of leadership roles, one of which was Senior Vice President at Cambridge Antibody Technology. Nigel has also held a number of Board level positions in companies such as Glythera and currently at Cell Medica. Additionally, he was formerly non-executive Director of Navion, Director and Founder of Nascient and, most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Furthermore, he was an entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.
Nigel has a PhD in biophysics from King’s College, London and a BSc in biochemistry from Imperial College London.
Allan Marchington is an experienced investor with a strong track record of success. In 2006 Allan and his Partners founded Apposite Capital, an international healthcare investment company based in London. While at Apposite, Allan has served on the Board of a number of companies including Calchan Ltd., Birdrock Bio Inc., Ambrx Inc., Ambit Biosciences Inc., Convergence Pharmaceuticals Ltd, and Sotera Wireless. Prior to establishing Apposite, Allan worked in a number of senior roles, including Entrepreneur in Residence, Abingworth Management and Senior Vice President, Millennium Pharmaceuticals Inc. based in Cambridge Mass. Prior to Millennium, Allan was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company which was successfully sold to Millennium in 2000. Allan has a PhD in Chemistry from the University of Liverpool and after leaving University, worked for seven years in a range of therapeutic areas at Pfizer.
Andrea is a Founder and Managing Partner of GHO Capital, a specialist investor in healthcare. He has three decades of investment banking experience, which has focused on healthcare since 1996.
Andrea created the European investment banking healthcare franchises of both JP Morgan and Goldman Sachs, advising on some of the most significant mergers and acquisitions for leading pharmaceutical, medical device, and hospital companies. He also advised emerging companies and private equity on mergers and acquisitions and debt or equity financing.
Prior to his role at GHO, Andrea was Vice Chairman of European Investment Banking and Global Co-head of Healthcare at JP Morgan. Previously, Andrea held the position of Partner, Managing Director at Goldman Sachs, and was responsible for a variety of roles, including membership of the company-wide Commitments Committee.
Andrea has a BA in economics from the University of North Carolina.
Founder and CEO
After a successful, 22-year-long career in investment banking based in London and New York, Gregg completed his MSc degree in immunology at Imperial College School of Medicine, London.
Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in collaboration with a small group of leading clinicians and immunologists who were pioneering this new type of medical treatment.
Gregg holds an MSc in immunology from Imperial College School of Medicine in London, as well as an MBA from the University of Chicago and a BA in biochemistry from Harvard University.